You are here
- Home
- Therapy Areas
- Oncology/Infection
A RANDOMISED, DOUBLE-BLIND, PARALLEL-GROUP, MULTICENTRE, PHASE II STUDY TO EVALUATE THE SAFETY AND PHARMACOLOGICAL ACTIVITY OF THE COMBINATION OF VANDETANIB (100 OR 300 MG/DAILY OR PLACEBO) WITH FULVESTRANT (LOADING DOSE), IN POSTMENOPAUSAL ADVANCED BREAST CANCER PATIENTS.
- Disease
- solid tumour
- Drug Name
- Caprelsa
- Generic Name
- vandetanib
- Sponsor
- AstraZeneca
- Drug Status
- Approved Medicine
- Phase
- II
- Start Date
- Dec 22, 2008
- Study Name
- D4200L00009
- Study Id
- D4200L00009
- Recruiting Status
- Closed
- Protocol Status
- Not Available
- Report Status
- Not Available
